Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GLSI-100 |
Synonyms | |
Therapy Description |
GLSI-100 comprises a peptide containing the ERBB2 (HER2)-derived epitope GP2 combined with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), which potentially induces an enhanced antitumor immune response against ERBB2 (HER2)-expressing tumor cells (Cancer Res (2023) 83 (5_Supplement): OT2-10-06). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GLSI-100 | GLSI 100|GLSI100 | HER2 (ERBB2) Vaccine 14 | GLSI-100 comprises a peptide containing the ERBB2 (HER2)-derived epitope GP2 combined with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), which potentially induces an enhanced antitumor immune response against ERBB2 (HER2)-expressing tumor cells (Cancer Res (2023) 83 (5_Supplement): OT2-10-06). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05232916 | Phase III | GLSI-100 | Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (FLAMINGO-01) | Recruiting | USA | POL | ITA | FRA | ESP | DEU | 0 |